HymonBio Co Ltd is based in Taicang, East China's Jiangsu province. [Photo/taicangdaily.com]

The Hymon® SARS-Cov-2 Test Kit developed by Taicang-based HymonBio Co recently won a gold award in the national competition for vitro diagnostics, local media reported on Jan 28.

The award-winning testing kit has been authorized by the FDA microbiological and equipment department in the United States and the King's College Hospital NHS Foundation in the United Kingdom. The company claims that the testing kit can detect the Delta and Omicron variants.

HymonBio Co was established in Taicang Port in 2015. Its co-founders were from the University of Texas and Chinese Academy of Sciences.

The company specializes in the development, production, and sale of precision-medicine and point-of-care diagnostics. Its products have obtained 11 Chinese medical device certificates, two CE certificates, and one FDA certificate.

HymonBio Co developed its first-generation SARS-CoV-2 Test Kit for human-to-human transmission in early 2020. The kit can detect the second, third, and fourth-generation epidemics transmitted from person to person. The kit also boasts a high accuracy in the diagnosis of viral pneumonia.

"For us, it is a time to show our responsibilities and an opportunity to play our technological strength," said Tan Miao, co-founder, chairwoman and general manager of HymonBio Co.